Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Why is Influx Healthtech Ltd falling/rising?

As of 31-Mar, Influx Healthtech Ltd's stock price is at 202.00, reflecting a decline of 5.85%. The stock is underperforming compared to benchmarks and its sector, with mixed moving average signals indicating short-term weakness.

As of 31-Mar, Influx Healthtech Ltd's stock price is falling, currently at 202.00, which reflects a decrease of 12.55 or 5.85%. This decline is evident in the stock's performance over various periods, including a 1-week drop of 4.63% and a year-to-date decrease of 10.66%. Compared to the benchmark Sensex, which has seen a smaller decline of 0.81% over the past week and 14.54% year-to-date, Influx Healthtech Ltd is underperforming.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 4.32%. Although the stock is trading higher than its 200-day moving average, it is below the 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a short-term weakness in price momentum. Additionally, while there has been a rise in investor participation, with a delivery volume increase of 35.9% against the 5-day average, this has not translated into a positive price movement. Overall, the combination of underperformance relative to benchmarks and sector, along with mixed moving average signals, contributes to the stock's current downward trend.

Which are the latest news on Influx Health.?